Gary L Olsen

Title: Gary L. Olsen: Innovator in Amyloid Peptide Modulation

Introduction

Gary L. Olsen is a notable inventor based in Mountainside, NJ (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of amyloid peptide aggregation. His work is crucial for understanding and treating amyloidogenic diseases.

Latest Patents

Gary L. Olsen holds a patent for "Modulators of β-amyloid peptide aggregation." This invention provides compounds that modulate natural β-amyloid peptide aggregation. The modulators comprise a peptide, preferably based on a β-amyloid peptide, that is entirely made of D-amino acids. The peptide typically consists of 3-5 D-amino acid residues, including at least two D-amino acid residues selected from D-leucine, D-phenylalanine, and D-valine. A particularly preferred embodiment of the invention is a retro-inverso isomer of a β-amyloid peptide, specifically a retro-inverso isomer of Aβ. The invention also includes pharmaceutical compositions and methods for diagnosing and treating amyloidogenic diseases.

Career Highlights

Gary L. Olsen is associated with Praecis Pharmaceuticals, Inc., where he has contributed to innovative research and development in the pharmaceutical industry. His work has been instrumental in advancing the understanding of amyloid-related conditions.

Collaborations

Gary has collaborated with notable colleagues, including Mark A. Findeis and Kathryn Phillips, to further enhance the research and development efforts in his field.

Conclusion

Gary L. Olsen's innovative work in the modulation of β-amyloid peptide aggregation represents a significant advancement in the fight against amyloidogenic diseases. His contributions continue to impact the pharmaceutical landscape positively.